Your session is about to expire
← Back to Search
MRI for ADHD Treatment Response Prediction
N/A
Waitlist Available
Led By Joseph Biederman, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group
Summary
This trial will test if certain brain markers can predict how well adults with ADHD will respond to stimulant medications.
Eligible Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
ADHD Clinical Global Impressions Scale - Improvement (CGI-I)
ADHD Clinical Global Impressions Scale - Severity (CGI-S)
Secondary study objectives
Connectomic Variation Prediction of Medicine Response
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: MethylphenidateExperimental Treatment1 Intervention
Adult subjects (ages 18-45) receiving a Methylphenidate derivative medication
Group II: AmphetamineExperimental Treatment1 Intervention
Adult subjects (ages 18-45) receiving an Amphetamine derivative medication
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MRI
2009
Completed Phase 2
~2810
Find a Location
Who is running the clinical trial?
Massachusetts Institute of TechnologyOTHER
99 Previous Clinical Trials
12,819,934 Total Patients Enrolled
1 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
41 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
Massachusetts General HospitalLead Sponsor
3,023 Previous Clinical Trials
13,317,889 Total Patients Enrolled
59 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
8,457 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
Joseph Biederman, MDPrincipal InvestigatorMassachusetts General Hospital
24 Previous Clinical Trials
6,374 Total Patients Enrolled
13 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
4,444 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a reason that makes it unsafe for you to take stimulant medication.Men and women between 18 and 55 years old.You are right-handed.You have been diagnosed with ADHD using a structured diagnostic interview.Your blood pressure is consistently high or your resting heart rate is too low or too high.
Research Study Groups:
This trial has the following groups:- Group 1: Amphetamine
- Group 2: Methylphenidate
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.